Pharma channel feed – Endpoints News

Pharma channel feed

It’s official: Controversial Marathon Pharmaceuticals bows out at PhRMA in wake of price gouging controversy

9 years ago

XBiotech shares crater as CHMP shudders at its application to sell Xilonix

9 years ago

Black box warning? No worries, Valeant bills Siliq as the ‘low-cost’ psoriasis alternative to rivals from Novartis, Eli Lilly

9 years ago

Vernalis shares slide after FDA turn thumbs down on their latest XR cold med

9 years ago

The list of the top 10 most expensive drugs on the planet will soon have a new opening

9 years ago

Is Tesaro playing a pricing game with Zejula? Not at all, says the CEO. And here's why

9 years ago

That turnaround on new FDA drug approvals? We’re right on schedule

9 years ago

Verily joins up with Duke, Stanford to enlist an army of consumers to put its next-gen sensor tech to the test — and in the public eye

9 years ago

Novartis ties up with the virtual biotech Parvus to try a new approach on Type 1 diabetes

9 years ago

Report: Hanmi’s failure to report patient death in olmutinib study broke South Korea’s medical laws

9 years ago

The UK isn't giving up on keeping the European Medicines Agency's HQ in London without a fight

9 years ago

Scoop: Juno recruits Sunil Agarwal as R&D chief, opening a Bay Area facility in research revamp

9 years ago

In a stunning setback, FDA spurns Eli Lilly’s marketing application for baricitinib, demands more data

9 years ago

New CEOs at Axovant, Destiny and Organovo mark a busy week for the biotech jobs scene

9 years ago

We don’t know when (exactly) Lilly will announce the FDA’s baricitinib decision, but watch out for the looming pricing squabble

9 years ago

Editas’ rivals appeal a recent setback on patent fight, mapping a global war for CRISPR supremacy

9 years ago

Roche, Biogen handing over $470M in cash to bag two drug programs from Bristol-Myers Squibb

9 years ago

The payer backlash against PTC’s deflazacort for Duchenne MD begins with some damning comparison shopping

9 years ago

Neurocrine bags an FDA OK for tardive dyskinesia, trumping Teva as it preps first commercial launch

9 years ago

Nine blockbuster drugs to watch are making their debut, aiming at a $16B prize in 2021

9 years ago

The FDA is getting its hands on a ‘human emulation system,’ and Emulate hopes they never let go

9 years ago

The FDA is keeping its partial hold on Repros’ Proellex

9 years ago

OncoMed shares crushed as Celgene-partnered lead drug flops and Bayer takes a pass on options

9 years ago

Geron survives, for now, but the jury at J&J is still out on the future of imetelstat

9 years ago

First page Previous page 328 329 330331332 333 334 Next page Last page